Aluminum/Magnesium Hydroxide (Maalox)

Aluminum/Magnesium Hydroxide, commonly known by the brand name Maalox, is an antacid combination medication used in horses to neutralize gastric acid and provide temporary relief from ulcer-related discomfort. This combination product contains two active ingredients that work together to buffer stomach acid: aluminum hydroxide and magnesium hydroxide. While not FDA-approved specifically for equine use, this human medication has been adapted for use in horses under veterinary guidance as a supportive therapy for gastric conditions. The medication is readily available over the counter, making it accessible for horse owners, though veterinary consultation is strongly recommended before initiating treatment.

The mechanism of action of aluminum/magnesium hydroxide is straightforward and effective. When administered orally, both aluminum hydroxide and magnesium hydroxide react chemically with hydrochloric acid in the stomach, neutralizing the acid and raising gastric pH. This neutralization provides rapid relief from the irritation and discomfort associated with excess stomach acid. The aluminum component tends to cause constipation while the magnesium component tends to cause loose stools, so the combination helps balance these effects. The duration of acid neutralization is relatively short, typically lasting one to two hours, which necessitates frequent dosing for sustained effect.

Aluminum/magnesium hydroxide is available primarily as an oral liquid suspension, which is the formulation most commonly used in horses. The liquid form allows for easy administration via oral dosing syringe and can be mixed with a small amount of feed if necessary. Tablet formulations exist but are less practical for equine use due to the large volumes required to achieve therapeutic doses in horses. The medication has a chalky taste that some horses tolerate well, while others may resist administration. Palatability can be improved by mixing with molasses or applesauce when veterinarian-approved.

The overall safety profile of aluminum/magnesium hydroxide in horses is considered good when used appropriately and for short-term periods. However, this medication should not be viewed as a primary treatment for equine gastric ulcer syndrome (EGUS) but rather as a supportive measure or bridge therapy. Modern proton pump inhibitors like omeprazole are far more effective for treating established gastric ulcers in horses. Veterinary supervision is important to ensure that antacid use does not mask symptoms of more serious gastrointestinal conditions that require different treatment approaches. Horse owners should understand that while antacids provide symptomatic relief, they do not heal ulcers and should be part of a comprehensive management plan developed with their veterinarian.

The primary indication for aluminum/magnesium hydroxide in horses is the temporary relief of gastric discomfort associated with excess stomach acid production. This medication is used as supportive therapy in horses experiencing symptoms of gastric irritation, including decreased appetite, mild colic signs, or behavioral changes that may indicate stomach discomfort. As an antacid, the medication works by directly neutralizing hydrochloric acid in the stomach, providing relatively rapid but short-lived relief. It is particularly useful as an adjunctive therapy while waiting for more definitive treatments like omeprazole to take full effect.

Aluminum/magnesium hydroxide is commonly employed in the management of equine gastric ulcer syndrome (EGUS), though it serves a supportive rather than primary therapeutic role. EGUS affects a significant percentage of horses, with studies suggesting that 50 to 90 percent of performance horses may have some degree of gastric ulceration. While proton pump inhibitors remain the gold standard for treating established ulcers, antacids can provide interim relief and may be used during diagnostic workups or when cost considerations limit access to more expensive medications. The medication helps reduce acid contact with ulcerated tissue, potentially decreasing pain and allowing horses to eat more comfortably.

Secondary uses of aluminum/magnesium hydroxide in equine medicine include management of horses with gastric sensitivity during stressful periods such as transport, competition, or changes in environment. Horses undergoing intensive training regimens may benefit from periodic antacid support, though this should not replace proper management practices that reduce ulcer risk. Some veterinarians recommend antacid administration before or after NSAID therapy as a protective measure, though the efficacy of this practice is debated and should not substitute for appropriate NSAID use and monitoring.

Additional clinical applications include use in horses recovering from gastric surgery or those with documented reflux esophagitis. The medication may be used in foals with gastric ulceration, though dosing must be carefully adjusted for the smaller body size. Some practitioners use aluminum/magnesium hydroxide as part of a broader gastroprotective protocol in hospitalized horses receiving multiple medications that may affect gastric health. The medication has also been used in horses with suspected hindgut acidosis, though its effectiveness in this application is limited due to neutralization occurring primarily in the stomach.

When selecting aluminum/magnesium hydroxide over alternative therapies, veterinarians typically consider factors such as cost, availability, and the nature of the gastric condition being treated. This medication is significantly less expensive than omeprazole and is readily available without prescription, making it accessible for many horse owners. However, its short duration of action and inferior efficacy compared to proton pump inhibitors means it is generally reserved for mild cases, temporary symptom management, or situations where other medications are unavailable. The decision to use antacids should always be made in consultation with a veterinarian who can properly diagnose the underlying condition and recommend appropriate treatment.

Dosing of aluminum/magnesium hydroxide in horses requires veterinary guidance to determine the appropriate amount based on the individual horse's weight, condition severity, and treatment goals. Unlike some equine medications with well-established protocols, antacid dosing in horses is largely extrapolated from human medicine and varies among practitioners. The general principle is that sufficient medication must be administered to neutralize gastric acid effectively, which in horses requires substantially larger volumes than human doses. Horse owners should never attempt to calculate doses independently but should rely on their veterinarian's specific recommendations for their horse.

Typical dosing guidelines for aluminum/magnesium hydroxide in adult horses range from 30 to 60 milliliters of liquid suspension given two to four times daily, though some protocols call for higher doses. The significant variation in recommended doses reflects the lack of robust pharmacokinetic studies in horses and the relatively short duration of acid neutralization. Some veterinarians recommend doses as high as 120 to 240 milliliters per administration for larger horses, particularly when treating acute symptoms. Weight-based dosing is important, and accurate assessment of body weight using a scale or weight tape helps ensure appropriate dosing. Ponies and miniature horses require proportionally smaller doses.

The duration of aluminum/magnesium hydroxide treatment depends on the clinical situation and response to therapy. For temporary symptomatic relief, treatment may last only a few days. When used as bridge therapy before omeprazole reaches full effectiveness (typically 3-5 days), the antacid may be administered during this initial period. Long-term antacid use is generally discouraged due to limited efficacy and potential for adverse effects with extended administration. Veterinarians typically reassess the treatment plan regularly and transition horses to more effective therapies when gastric ulceration is confirmed.

Administration of aluminum/magnesium hydroxide is most commonly performed using an oral dosing syringe inserted into the corner of the horse's mouth. The liquid suspension should be shaken well before use to ensure uniform distribution of the active ingredients. The medication is typically given on an empty stomach for maximum acid neutralization, ideally 30 minutes to one hour before feeding. However, some veterinarians recommend administration with or after a small amount of feed to improve tolerance and reduce the risk of the horse spitting out the medication. For horses that resist oral syringing, the liquid can sometimes be mixed with a small amount of grain or sweet feed, though this may reduce effectiveness.

If a dose of aluminum/magnesium hydroxide is missed, horse owners should administer the medication as soon as they remember, provided it is not too close to the next scheduled dose. Due to the short duration of action, missing a single dose is unlikely to cause significant problems, though it may result in a temporary return of symptoms. Owners should never double the dose to make up for a missed administration, as this could lead to gastrointestinal disturbances. If multiple doses are missed, owners should contact their veterinarian for guidance on resuming the treatment schedule.

Completing the recommended course of treatment is important even if symptoms appear to improve before the prescribed duration ends. Early discontinuation may result in symptom recurrence, and underlying conditions may not be adequately addressed. However, unlike antibiotics where incomplete courses promote resistance, antacids can generally be safely discontinued when no longer needed. Horse owners should work with their veterinarian to determine when it is appropriate to stop treatment and whether transition to other medications or management changes is warranted. Regular follow-up allows the veterinarian to assess treatment response and make necessary adjustments.

Aluminum/magnesium hydroxide is generally well-tolerated by horses when used at appropriate doses for short-term periods. The combination of aluminum and magnesium compounds was specifically designed to balance the opposing gastrointestinal effects of each component, reducing the likelihood of significant digestive disturbances. Most horses experience no adverse effects during treatment, particularly when the medication is used as directed under veterinary supervision. However, horse owners should be aware of potential side effects and monitor their horses during treatment to ensure early detection of any problems.

The most common side effects associated with aluminum/magnesium hydroxide relate to alterations in gastrointestinal motility and stool consistency. Aluminum compounds tend to cause constipation by reducing intestinal motility and absorbing water from the intestinal contents. Conversely, magnesium compounds tend to draw water into the intestines and promote loose stools. While the combination product is formulated to balance these effects, individual horses may respond differently, experiencing either constipation or diarrhea. Mild changes in manure consistency are generally not concerning, but significant or persistent alterations should be reported to the veterinarian.

Moderate side effects that may occur with aluminum/magnesium hydroxide use include decreased appetite, mild abdominal discomfort, and changes in drinking behavior. Some horses may develop an aversion to the medication due to its taste or texture, making subsequent administration challenging. Phosphorus depletion is a concern with long-term aluminum-containing antacid use, as aluminum binds phosphorus in the gastrointestinal tract and prevents its absorption. This effect is more significant with extended use and can lead to weakness, bone demineralization, and poor performance. Magnesium toxicity is rare but possible in horses with kidney dysfunction, as impaired renal function prevents normal magnesium excretion.

Serious side effects from aluminum/magnesium hydroxide are uncommon when the medication is used appropriately. However, significant electrolyte imbalances can develop with prolonged high-dose use, particularly in horses with underlying health conditions. Signs of electrolyte disturbance may include weakness, muscle tremors, cardiac irregularities, and neurological abnormalities. Additionally, antacids can interfere with the absorption of other medications, potentially reducing the effectiveness of concurrent treatments. Allergic reactions, while rare, are possible and may manifest as skin reactions, swelling, or respiratory distress.

Rare side effects and situations requiring immediate veterinary attention include severe diarrhea, signs of colic, complete loss of appetite, marked lethargy, or any symptoms of an allergic reaction. Horses that develop signs of intestinal obstruction, such as absence of manure production combined with abdominal pain, require emergency evaluation. Long-term use monitoring should include periodic assessment of electrolyte levels, particularly phosphorus and magnesium. Any horse showing unexpected deterioration during antacid therapy should be examined promptly, as this may indicate progression of the underlying condition or development of complications.

Aluminum/magnesium hydroxide should not be used in horses with known hypersensitivity to either aluminum or magnesium compounds. While true allergic reactions to antacids are rare, horses that have previously experienced adverse reactions to these medications should not receive them again. Cross-reactivity may occur with other aluminum or magnesium-containing products, so a thorough medication history is important before initiating treatment. Horse owners should inform their veterinarian of any previous adverse reactions to medications, supplements, or other products.

Horses with significant kidney disease represent an important population in which aluminum/magnesium hydroxide use requires extreme caution or avoidance. The kidneys are responsible for excreting excess magnesium from the body, and horses with impaired renal function cannot efficiently eliminate magnesium absorbed from the medication. This can lead to hypermagnesemia, a potentially serious condition characterized by muscle weakness, cardiovascular abnormalities, and in severe cases, respiratory depression. Similarly, aluminum accumulation can occur in horses with kidney disease, potentially contributing to neurological effects. Veterinary assessment of kidney function should precede antacid use in any horse with suspected or documented renal impairment.

Life stage considerations affect the appropriateness of aluminum/magnesium hydroxide use. Pregnant mares should use this medication only under direct veterinary supervision, as the effects of chronic antacid use on fetal development have not been well studied in horses. Nursing mares may pass components of the medication through milk, though significant effects on foals are unlikely at typical doses. Foals have different gastrointestinal physiology than adult horses, and dosing must be carefully adjusted when antacids are deemed necessary. Very young foals may be more susceptible to electrolyte disturbances from antacid use. Geriatric horses with declining kidney function should be evaluated before starting antacid therapy.

Other medical conditions may contraindicate or require cautious use of aluminum/magnesium hydroxide. Horses with diagnosed hypophosphatemia should not receive aluminum-containing antacids, as further phosphorus depletion could worsen this condition. Horses with chronic gastrointestinal diseases affecting motility may experience exacerbation of their condition. The medication should not be used as a substitute for proper diagnostic workup in horses with persistent gastrointestinal symptoms, as antacid use may mask symptoms of serious conditions requiring different treatment. Horses on restricted electrolyte diets or those being treated for metabolic conditions should have antacid use evaluated in the context of their overall management plan. Competition horses should verify that antacid use is permissible under the rules of their governing organization, as some regulatory bodies have specific guidelines regarding medication use.

Aluminum/magnesium hydroxide interacts with numerous other medications through a common mechanism: alteration of gastrointestinal pH and direct binding of drug molecules in the stomach. These interactions can significantly reduce the absorption and effectiveness of concurrently administered medications. The most clinically important interaction principle is that antacids should generally be administered separately from other oral medications, with a minimum interval of two hours before or after other drugs. This separation allows medications to be absorbed before the antacid can interfere with their uptake.

Several important medication classes interact with aluminum/magnesium hydroxide and require careful management. Tetracycline antibiotics, including doxycycline and oxytetracycline, bind strongly to aluminum and magnesium ions, forming insoluble complexes that cannot be absorbed from the gastrointestinal tract. This interaction can reduce antibiotic effectiveness to clinically insignificant levels, potentially leading to treatment failure. Fluoroquinolone antibiotics such as enrofloxacin also interact with antacids through similar mechanisms and should be separated by at least two to four hours. Sulfonamide antibiotics may have reduced absorption when given with antacids.

Moderate interactions occur between aluminum/magnesium hydroxide and several other medication classes used in equine medicine. Non-steroidal anti-inflammatory drugs (NSAIDs) may have altered absorption when administered with antacids, though the clinical significance varies by specific drug. Some veterinarians intentionally combine antacids with NSAIDs in an attempt to reduce gastric side effects, but this practice may actually impair NSAID absorption without providing meaningful gastroprotection. Ranitidine and other H2 receptor antagonists may have reduced effectiveness when gastric pH is already elevated by antacid use. Certain antifungal medications, particularly ketoconazole and itraconazole, require acidic conditions for absorption and may be significantly less effective when administered with antacids.

Considerations for competition horses regarding drug interactions extend beyond therapeutic concerns to include regulatory compliance. Antacid use itself may not be prohibited in many equine disciplines, but interactions with other medications could affect detection times and withdrawal periods. Horses receiving multiple medications should have their complete drug regimen reviewed to ensure no unexpected interactions affect either therapeutic outcomes or competition eligibility. Some supplements, including certain mineral and vitamin preparations, may also interact with antacids. Iron supplements, for example, may have reduced absorption when administered with aluminum-containing antacids. Horse owners should provide their veterinarian with a complete list of all medications, supplements, and treatments their horse receives to allow proper assessment of potential interactions.

Monitoring horses receiving aluminum/magnesium hydroxide should include observation for changes in appetite, manure production and consistency, and overall demeanor. While the medication is generally safe for short-term use, owners should watch for signs of gastrointestinal disturbance such as decreased fecal output, excessively loose stools, or any indication of abdominal discomfort. Horses on prolonged antacid therapy, which is generally discouraged but sometimes necessary, should have periodic blood work to assess phosphorus levels and kidney function. Veterinary follow-up appointments allow assessment of treatment response and determination of whether continued antacid use is appropriate.

Special populations require additional consideration when using aluminum/magnesium hydroxide. Foals have immature gastrointestinal and renal systems that may handle antacids differently than adult horses, necessitating careful dose adjustment and monitoring. Geriatric horses often have some degree of kidney function decline, even if subclinical, which may affect their ability to handle magnesium loads from antacid use. Pregnant and lactating mares should use antacids only when clearly needed and under veterinary supervision. Horses with a history of metabolic conditions, including pituitary pars intermedia dysfunction (PPID) or equine metabolic syndrome (EMS), should be monitored for any effects on their overall health status during antacid therapy.

For competition and performance horses, aluminum/magnesium hydroxide use must be considered in the context of regulatory requirements. While antacids are not prohibited substances under most equine competition rules, verification of current regulations is essential before competition. The Federation Equestre Internationale (FEI), United States Equestrian Federation (USEF), and various racing commissions may have specific guidelines regarding antacid use or documentation requirements. Detection times for antacid components are generally not a concern, but horses receiving multiple medications should have their complete protocol reviewed by a veterinarian familiar with competition drug rules. Maintaining accurate medication records is important for compliance and helps protect against inadvertent rule violations.

Safe handling of aluminum/magnesium hydroxide presents minimal human health concerns compared to many veterinary medications. The medication is non-toxic to humans at exposure levels that might occur during administration to horses. Basic hygiene practices, including hand washing after handling the medication, are sufficient precautions. The liquid suspension can be messy if spilled, but no special cleanup procedures are required beyond normal cleaning. Eye contact with the medication may cause mild irritation and should be addressed by rinsing with water.

Long-term use considerations are important because aluminum/magnesium hydroxide is not intended for extended administration. Chronic antacid use in horses can lead to phosphorus depletion due to aluminum binding phosphorus in the gastrointestinal tract and preventing absorption. This can result in hypophosphatemia, characterized by weakness, poor performance, and potentially bone abnormalities. Additionally, continuous acid neutralization may affect normal digestive processes and potentially alter the gastrointestinal microbiome. Horses requiring ongoing gastric acid suppression should generally be transitioned to proton pump inhibitors such as omeprazole, which provide more effective and sustained acid control with a better-established safety profile for long-term use in horses.

Proper storage of aluminum/magnesium hydroxide helps maintain the medication's effectiveness throughout its shelf life. The liquid suspension should be stored at room temperature, typically between 59 and 86 degrees Fahrenheit (15-30 degrees Celsius). Extreme temperatures should be avoided, as freezing may cause separation of the suspension components, and excessive heat may accelerate degradation of the active ingredients. In barn environments, this means keeping the medication in a climate-controlled area when possible, or at least protected from direct sunlight and extreme temperature fluctuations that can occur in tack rooms or storage areas.

Handling and safety considerations for aluminum/magnesium hydroxide are straightforward, as the medication presents minimal hazards to humans and animals. The suspension should be shaken thoroughly before each use to ensure uniform distribution of the active ingredients, as settling naturally occurs during storage. Oral dosing syringes used to administer the medication should be rinsed after each use to prevent residue buildup. There are no special protective equipment requirements for handling this medication, though basic hygiene practices such as hand washing after administration are appropriate. In case of accidental human ingestion, medical attention is generally not required unless large amounts are consumed, but consultation with a poison control center is advisable.

Expiration dates on aluminum/magnesium hydroxide products should be strictly observed, as the medication may lose effectiveness over time. Most liquid antacid preparations have a shelf life of one to two years from manufacture when stored properly. Visual inspection before each use can identify signs of degradation, including unusual color changes, separation that does not resolve with shaking, or unusual odor. Expired medication should not be used and should be disposed of appropriately. Disposal of unused antacid suspension can typically be done through regular household waste or community medication take-back programs, as this medication does not pose significant environmental concerns. However, local regulations should be followed for medication disposal, and flushing medications down drains or toilets is generally discouraged. Opened containers may have shorter effective shelf lives than unopened products, particularly if contaminated during use.

Draft horses, including breeds such as Clydesdales, Percherons, Shires, and Belgians, require dose adjustments for aluminum/magnesium hydroxide based on their larger body mass. These breeds typically weigh between 1,600 and 2,200 pounds or more, substantially more than average light horse breeds. The proportionally larger stomach volume in draft breeds means that higher absolute doses may be needed to achieve adequate acid neutralization. However, veterinary guidance is essential for calculating appropriate doses, as simply scaling up from light horse doses may not account for metabolic differences between breed types. Draft horses generally tolerate antacids well, and the medication can be administered using standard techniques with appropriately larger dosing syringes or multiple syringe volumes.

Light horse breeds and warmbloods, representing the majority of horses receiving aluminum/magnesium hydroxide, typically follow standard dosing recommendations. Breeds in this category include Thoroughbreds, Quarter Horses, Arabians, warmbloods, and various sport horse types, generally weighing between 900 and 1,400 pounds. Performance horses in these breeds may be at higher risk for gastric ulceration due to intensive training and competition schedules, making them more likely candidates for antacid therapy. Standard dosing protocols apply to these breeds, with adjustments based on individual weight and clinical response. Competition horses should verify that antacid use is permissible under their specific discipline's regulations.

Ponies and miniature horses require careful dose reduction when aluminum/magnesium hydroxide is prescribed. These smaller equines may weigh as little as 150 pounds for miniature horses to around 900 pounds for larger ponies, representing a significant size range that affects dosing. More precise weight measurement using a scale rather than weight tape is particularly important for small equines, as percentage errors in weight estimation translate to proportionally larger dosing errors. Additionally, ponies and miniatures are more prone to metabolic conditions such as equine metabolic syndrome, which may influence overall treatment decisions. Their smaller gastrointestinal volume means that even moderate doses can have significant effects on gastric pH.

Breed-specific sensitivities and genetic conditions may influence aluminum/magnesium hydroxide use indirectly through their effects on overall health status or concurrent medications. Quarter Horses with HYPP (Hyperkalemic Periodic Paralysis) require careful monitoring of electrolyte status, and while antacids do not directly affect potassium levels, attention to overall electrolyte balance is appropriate. Horses with PSSM (Polysaccharide Storage Myopathy) may have exercise-related discomfort that could be confused with gastric discomfort, making accurate diagnosis important before initiating antacid therapy. Friesians with their predisposition to megaesophagus may have difficulty with oral medication administration and may need alternative treatment approaches. Appaloosas prone to equine recurrent uveitis are often on systemic medications that may interact with antacids, requiring coordination of treatment timing.

Within the antacid class, several alternative products may be considered instead of or in addition to aluminum/magnesium hydroxide. Other aluminum or magnesium-based antacids, such as aluminum hydroxide alone or magnesium hydroxide alone (milk of magnesia), work through similar mechanisms but with different side effect profiles. Calcium carbonate antacids (such as Tums) provide acid neutralization and are sometimes used in horses, though the calcium load may be a consideration in certain situations. Sucralfate, while technically a mucosal protectant rather than a true antacid, is sometimes grouped with acid-neutralizing medications and provides a different mechanism of gastric protection by forming a protective coating over ulcerated tissue.

Different drug classes offer alternative approaches to managing gastric acid in horses. Proton pump inhibitors, particularly omeprazole (marketed as GastroGard and UlcerGard for horses), represent the gold standard for equine gastric ulcer treatment and prevention. Omeprazole works by blocking the hydrogen-potassium ATPase enzyme in gastric parietal cells, providing profound and sustained acid suppression that antacids cannot match. H2 receptor antagonists, including ranitidine, famotidine, and cimetidine, reduce acid secretion by blocking histamine receptors on parietal cells. These medications provide intermediate efficacy between antacids and proton pump inhibitors and may be used when omeprazole is unavailable or unaffordable. Misoprostol, a prostaglandin analog, offers mucosal protection through a different mechanism and may be used in specific situations.

Complementary therapies and management changes often accompany aluminum/magnesium hydroxide use in a comprehensive approach to gastric health. Feeding management adjustments, including providing frequent small meals, ensuring constant access to forage, and reducing grain intake, help minimize gastric acid effects on the stomach lining. Alfalfa hay or chaff may provide natural buffering due to its calcium content and protein composition. Stress reduction strategies, including appropriate turnout, consistent routines, and minimizing transportation when possible, address underlying risk factors for ulcer development. Various supplements marketed for gastric support are available, though their efficacy varies and veterinary guidance is recommended when selecting products. Any substitution of medications or addition of supplements should be discussed with a veterinarian to ensure appropriate treatment for the horse's specific condition.